Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL-C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 (ots/PRNewswire) - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP* and EAS* low-density lipoprotein ...